The epidemic form of the hemolytic uremic syndrome (HUS), beginning with an acute gastroenteritis, has been associated with a verocytotoxin-producing Escherichia coli infection. The endothelial cell is believed t o play an important role in the pathogenesis of HUS. Endothelial cell damage by verocytotoxin-1 (VT-1) in vitro is potentiated by the additional exposure of inflammatory mediators, such as tumor necrosis factor-a (TNF-a). Preincubation of human umbilical vein endothelial cells (HUVEC) with TNF-a resulted in a 10-t o 100-fold increase of specific binding sites for 1251-VT-l. Furthermore, interleukin-1 (IL-1), lymphotoxin (TNF-p), and lipopolysaccharide (LPS) also markedly increase VT-1 binding. Several hours' exposure t o TNF-a was enough t o enhance the number of VT-1 receptors on the endothelial cells for 2 days. The H E HEMOLYTIC uremic syndrome (HUS) is a clini-T cal syndrome consisting of the triad of hemolytic anemia, thrombocytopenia, and acute renal failure. Although the exact pathogenesis is still unknown, it is believed that endothelial cell damage plays a central role in this syndrome and that one of the requirements for an agent to cause HUS is its ability to injure endothelial cells. The epidemic form of HUS, which starts with an acute, often bloody, gastroenteritis, is mostly seen in children.' In 1985, Karmali et al associated this form of HUS with an infection of verocytotoxin-or Shiga-like toxin-producing Escherichia coli infection.2 Since then, several other investigators across the world have been able to confirm this association. A family of three verocytotoxins or Shiga-like toxins has been described: verocytotoxin-1 (VT-l), verocytotoxin-2 (Shigalike toxin 11), and verocytotoxin-2 ~a r i a n t .~?~ The functional receptor for these toxins was recently identified as the glycosphingolipid, globotriaosylceramide ( G b O~e~c e r ) .~,~ This receptor has also been found in the human kidney7 and on cultured human endothelial cells.8
T cal syndrome consisting of the triad of hemolytic anemia, thrombocytopenia, and acute renal failure. Although the exact pathogenesis is still unknown, it is believed that endothelial cell damage plays a central role in this syndrome and that one of the requirements for an agent to cause HUS is its ability to injure endothelial cells. The epidemic form of HUS, which starts with an acute, often bloody, gastroenteritis, is mostly seen in children.' In 1985, Karmali et al associated this form of HUS with an infection of verocytotoxin-or Shiga-like toxin-producing Escherichia coli infection.2 Since then, several other investigators across the world have been able to confirm this association. A family of three verocytotoxins or Shiga-like toxins has been described: verocytotoxin-1 (VT-l), verocytotoxin-2 (Shigalike toxin 11), and verocytotoxin-2 ~a r i a n t .~?~ The functional receptor for these toxins was recently identified as the glycosphingolipid, globotriaosylceramide ( G b O~e~c e r ) .~,~ This receptor has also been found in the human kidney7 and on cultured human endothelial cells. 8 In most HUS patients, the endothelial damage is primarily concentrated in the kidney endothelium, whereas in severe HUS patients the endothelial damage extends to other organs, such as pancreas and brain.9 When we investigated whether local factors generated during coagulation or inflammation can make the endothelium more vulnerable to verocytotoxins, we observed that endothelial damage by VT-1 depends on the additional presence of the inflammatory mediator tumor necrosis factor-a (TNF-a). lO Similarly, two other groups have recently found that endothelial cells become more sensitive to other related toxins, Shiga-like toxin I1 and Shiga toxin, when they are simultaneously exposed to TNF-a.11J2 The inflammatory mediators TNF-a and interleukin-1 (IL-1) are produced and released by monocytes13 and mesangial cell^,^^^^^ and hence may play a local role in the kidney. In this report, we extend our observations and demonstrate that the inflammatory mediators TNF-a and IL-1 make the endothelial cells sensitive to VT-1 by the induction of VT-1 receptors on their surface.
TNF-orinduced increase in VT-1 binding could be inhibited by simultaneous addition of the protein synthesis inhibitor cycloheximide. Glycolipid extracts of TNF-ortreated cells tested on thin-layer chromatography demonstrated an increase of globotriaosylceramide (GbOsescer), a functional receptor for VT-1, which suggests that preincubation of human endothelial cells with TNF-a leads t o an increase in GbOsescer synthesis in these cells. We conclude from this study that TNFrv and IL-1 induce one (or more) enzyme(s) that is (are) rate-limiting in the synthesis of the glycolipid VT-1 receptor, GbOsescer. These in vitro studies suggest that, in addition t o VT-1, inflammatory mediators play an important role in the pathogenesis of HUS. 0 1992 b y The American Society of Hematology.
MATERIALS AND METHODS

Materials
Purified VT-1 was prepared in the laboratory of Dr Karmali (1.2 mg proteinlml; CDso vero-cells: titer to 10-9).16 Endotoxin content of the VT-1 preparation was less than 0.05 EUImL by Limulus amoebocyte lysate assay (E-Toxic, Sigma Chemicals, St Louis, MO) at detection level of 0.05 to 0.10 EU/mL. Monoclonal antibody PHI against VT-1 was a generous gift of Dr C. Lingwood (Department of Microbiology, Hospital for Sick Children, Toronto, Canada). M199 medium supplemented with 20 mmol/L HEPES was obtained from Flow Laboratories (Irvine, Scotland); tissue culture plastics were from Costar (Cambridge, MA). A crude preparation of endothelial cell growth factor was prepared from bovine brain as described by Maciag et al." Human serum was obtained from the local blood bank and was prepared from fresh blood of healthy donors, pooled, and stored at 4°C; it was not heat-inactivated before use. Newborn calf serum (NBCS) and fetal calf serum (FCS) were from GIBCO (Grand Island, NY) and Boehringer Mannheim (Mannheim, Germany), respectively; they were heat-inactivated before use (at 56°C for 30 minutes). Heparin was purchased from Leo Pharmaceuticals (Weesp, The Netherlands). Penicillinlstreptomycin was from Boehringer Mannheim (Mannheim, Germany). Human fibronectin was a gift of J.A. van Mourik, Central Laboratory of the Red Cross Blood Transfusion Service (Amsterdam, The Netherlands). Pyrogen-free human serum albumin (HSA) was purchased from the Central Laboratory of the Red Cross Blood Transfusion Service (Amsterdam, The Netherlands). a-Thrombin was obtained from Sigma Chemicals. 
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Human recombinant TNF-a and lymphotoxin (TNF-p) were gifts from Jan Tavernier (Biogent, Gent, Belgium). The TNF-a preparation contained 2.45 x lo-' U/mg protein and less than 40 ng lipopolysaccharide (LPS) per mg protein; the specific activity of TNF-p was 1.6 x lo6 U/mg protein. Human recombinant IL-6 (expressed in yeast cells) was prepared in the Laboratory of Molecular Biology, State University, Gent, Belgium; it was biologically active and had a specific activity of 1.4 x lo8 U/mg protein as tested on 7TD1 cells. Human recombinant IL-la and IL-1p were gifts of S. Gillis (Immunex, Seattle, WA); they had a specific activity of 108U/mg. LPS of E coli serotype 0128-B12 was obtained from Sigma Chemicals. 35S-methionine and NalzI-iodine were purchased from Amersham (Amersham, UK). Iodo-gen iodination reagent was obtained from Pierce (Rockford, IL). Anti-Tja serum,I8 serum that contains antibodies against Pk (GbOse3cer), P (globotetraosylceramide [GbOse4cer]), and PI blood group antigens, was obtained from DiaMed (Morat, Murten, Switzerland). Chloroform, methanol, and hexane was obtained from Merck (Darmstadt, Germany). Plastic-coated silica gel F1500 thin-layer chromatography (TLC) plates were from Schleicher and Schuell (Dassel, Germany). Polyisobutylmetbacrylate was obtained from Polysciences (Washington, MD). A standard mixture of pure neutral glycolipids containing Galpl-lCeramide(Cer)(CMH),
l C e r ( G b O s e J c e r ) , GalNac~l-3Galal-4Galpl-4Glc~l-lCer(GbOse4cer), and GalNaca1-3GalNacpl-3Galal-4Galpl-4Glcpl-1Cer (Forssman pentasaccharide) was from BioCarb (Lund, Sweden). X-OMAT x-ray film was from Eastman Kodak (Rochester, NY).
Methods
Endothelial cells from human umbilical vein (HU-VEC) and from human femoral vein were isolated by collagenase treatment,I9 cultured, and characterized as previously described.20,21
The endothelial cells were seeded in fibronectin-coated 10-cm2 wells and cultured in M199 medium supplemented with 20 mmol/L HEPES (pH 7.4), 10% human serum (HS), 10% NBCS, L-glutamine, 5 U/mL heparin, and 150 pg/mL crude preparation of endothelial cell growth factor under 5% C02 and 95% air at 37°C. When the cells reached confluency, they were detached by trypsin/ EDTA and seeded in 2-cmZ fibronectin-coated dishes with a split ratio of 1:3. HUVEC in the experiments were used after two to four passages, and femoral vein endothelial cells after six or seven passages. The medium was renewed every 2 or 3 days.
For these experiments, cells were released with trypsin/EDTA and seeded in confluent density in 2-cm2 fibronectin-coated plates and cultured in complete culture medium (400 pL/well). Instead of 10% human serum and 10% NBCS, 20% FCS was used, because neutralizing activity of NBCS was found against VT-1 and because of potential neutralizing activity against VT-1 in human pooled serum. When confluency was reached, medium was renewed and the cells were preincubated for 24 hours with TNF-a (500 U/mL). The next day, the medium was renewed and purified VT-1 (17 pmol/L to 17 nmol/L) with or without TNF-a or a-thrombin was added to the wells. After 24 hours' incubation, the cells were washed with M199 medium, and the viable cells released with trypsiniEDTA and counted in a hemocytometer. The experiments were performed in duplicate.
Protein synthesis was determined by assay of the incorporation of 35S-labeled methionine (0.25 pCi/mL added to complete medium) in 35S-proteins during an 8-or 24-hour incubation period. After incubation, the cells were washed and cellular 35S-labeled proteins were precipitated by adding 10% trichloroacetic acid. Precipitated radioactivity was dissolved in 0.3 mL 0.3 mol/L NaOH and counted in a liquid scintillation counter. Protein Cell culture. Cytotoxici@ assay.
Other assays.
was determined according to the method of Lowry et alu using bovine serum albumin (BSA) as a standard. Cell counts were performed in triplicate with a hemocytometer.
VT-1 was radiolabeled with NaIzI according to the Iodogen procedure.u Four preparations of purified VT-1 were iodinated to specific activities of 2.7,4.1,21, and 37 pCi/pg of protein. All preparations gave similar results. The binding assay was performed as follows: after the incubation period at 37°C with or without inflammatory mediators, the endothelial cell cultures in 24-well plates were washed with M199 medium plus 0.1% HSA. Subsequently, the cells were incubated for 3 hours with 0.3 or 1.0 nmol/L lZ1-VT-1 in M199 medium plus 0.1% HSA at 0°C. After this incubation, the supernatant fluid was aspirated, the cells were washed five times with M199 medium plus 0.1% HSA, and total cell protein was solubilized in 400 pL lmol/L sodium hydroxide at room temperature. Radioactivity of the endothelial cells was measured in a gamma-counter. Nonspecific binding was determined by assay of 1251-VT-l binding in the presence of a 100-fold excess of unlabeled VT-1. Cellular specific binding was determined by subtracting the nonspecific binding from the cellular binding of 1251-VT-l determined in the absence of unlabeled VT-1. To study the effect of anti-Tja serum (blocking of the binding of VT-1 to GbOse3cer), anti-Tja serum in M199 medium plus 0.1% HSA was added 2 hours before and during the binding assay with 1251-VT-1.
Confluent HUVEC in 162-cm2 flasks were incubated for 24 hours with or without TNF-a (500 U/mL). Subsequently, the glycolipids were extracted as described by Lingwood et aF; in short, the cells were trypsinized, hawested with ice-cold phosphate-buffered saline (PBS), and spun down by 3-minute centrifugation (3,000 rpm) at 4°C. The pellet was washed three times with PBS. The pellet was finally resuspended in PBS, and 20 vol of chloroform/methanol (2:1, vol/vol) was added. Cell debris was removed by filtration through glass-wool. One volume of water was added and partitioned. The lower phase was dried and incubated at 37°C for 2 hours in 0.4 mol/L KOH in ethanol; 2 vol (vol/vol) of chloroform was added and the mixture was partitioned against 2 vol of water. The lower phase was separated and frozen at -20°C until TLC studies were performed.
The lower phase from the extraction above was dried and resuspended in chloroform/methanol (2:l). Samples were separated on a silica gel TLC plate using ch1oroform:methanol:water (65:25:4). After separation, the plate was soaked three times for 1 minute in 0.01% polyisobutylmethacrylate in hexane and air-dried, followed by overnight incubation in PBS supplemented with 1% BSA and 0.05% Tween 20. Subsequently, the plate was incubated with 50 mL VT-1 solution (15 nmol/L unlabeled and 1.5 nmol/L IzI-VT-1 in 1% BSA and 0.05% Tween in PBS) for 4 hours at 4°C. The plate was extensively washed with 0.05% Tween 20 and 1% BSA in PBS, air-dried, and exposed overnight to X-OMAT x-ray film.
Binding of 1251-VT-l to human endothelial cells.
Extraction of glycolipids.
TLC.
RESULTS
Cytotoxicity of VT-I Toward Human Endothelial Cells
VT-1 caused a decrease in cell viability of endothelial cells when they had been preincubated with the inflammatory mediator TNF-a (Fig 1A) . only four of six independent cell cultures. Under all conditions, no cytotoxicity was found when VT-1 was inactivated by heat treatment before addition or when VT-1 was preincubated with monoclonal antibodies to VT-1.
Preincubation of the cells with thrombin (0.1 to 1 U/mL) did not change the sensitivity of endothelial cells for VT-1 (three independent experiments; not shown). Similar results were obtained when endothelial cells from adult human vein (vena femoralis) were used (Fig 2A) . Verocytotoxin may inhibit eukaryotic protein synthesis by depurination of a single adenine residue from the 28s RNA component of the ribosome,% which may result in the inhibition of the interaction of elongation factor-1 with the ribosome. Cellular protein synthesis was measured by assaying the incorporation of 35S-methionine into total cellular protein. Incubation of the cells with VT-1 alone did not affect the protein synthesis over a 24-hour period ( Fig  1B) . However, when the cells were preincubated for 24 hours with TNF-a, the protein synthesis rate was decreased dramatically by VT-1, whereas the protein synthesis was not decreased by TNF-a alone. As shown in Fig 2B, the observed decrease depended on the concentrations of both VT-1 and TNF-a.
Binding of VT-1 to Human Endothelial Cells
To evaluate whether the enhanced VT-1 sensitivity of endothelial cells caused by TNF-a was due to an increase in VT-1 receptors on the cell surface, binding experiments with lZ5I-VT-l were performed. TNF-a induced an increase in VT-1 binding after a 6-to 8-hour lag period; this increase continued for up to 48 hours (Fig 3) . The increase was due to an increase in specific binding of 1251-VT-l, as nearly all lEI-VT-1 binding could be displaced by an excess of unlabeled VT-1. No change in VT-1 binding was observed in nontreated cells (Fig 3) . In six independent experiments with confluent HUVEC of different donors, 24-hour incubation with 500 U/mL TNF-a resulted in a %fold increase in specific VT-1 binding (range, 13-to 90-fold).
Subconfluent HUVEC displayed a higher basal VT-1 binding than highly confluent cells, as is shown in Fig 4 for a representative experiment. When the same cells were incubated for 18 hours with TNF-a, the binding of VT-1 increased for all cells, but the relative increase was larger in highly confluent HUVEC. In further experiments we have used highly confluent cells.
The effect of TNF-a on lZ5I-VT-l binding was concentration-dependent (Fig 5A) . The binding saturated at approximately 10 nmol/L VT-1 (Fig SB) . From analysis of Scatchard plots of the binding curves ( Fig 5C, Table l) , it was concluded that the number of specific VT-1 binding sites increased by one or two orders of magnitude after 24 hours of incubation with TNF-a, whereas the apparent affinity of VT-1 binding to HUVEC did not significantly change (Table 1) . Similarly, in human femoral vein endothelial cells, the number of VT-1 binding sites increased 14-fold after a 24-hour incubation period with 100 U/mL TNF-a from 2 X lo5 VT-1 binding sites/cell in control cells to 29 x 105 VT-1 binding sites in TNF-a-treated cells.
In addition to TNF-a, IL-la, IL-lp, TNF-P, and bacterial LPS induced a more than 10-fold increase in specific VT-1 binding to HUVEC (Fig 6) . Thrombin induced only a threefold increase, whereas IL-6 (5 or 50 U/mL) did not significantly alter VT-1 binding. The increase induced by 10 pg/mL LPS was twofold less than that induced by 500 U/mL TNF-a. LPS increased VT-1 binding in a concentration-dependent manner (Fig 7) . As can be seen in Fig 7,24 hours' incubation with small amounts of TNF-a and LPS resulted in an additional increase in the binding of VT-1 to HUVEC.
As the half-life of TNF-a in plasma is relatively short (several minutes),= we have evaluated how long after period without TNF-a, after which the VT-1 binding was assayed. The results of two independent experiments are given in Table 2 . Six hours of incubation with TNF-a was enough to detect an increase in VT-1 binding after a 24-or 48-hour incubation. This suggests that the increased sensitivity of endothelial cells for VT-1 can last for at least 1 day after the disappearance of inflammatory mediators.
The Nature of TNF-a-Induced VT-I Binding to Endothelial Cells
GbOse3cer has been identified as a receptor for VT-1 in various cells.26 To evaluate whether the increase in specific VT-1 binding was due to an increase in the exposure of GbOse3cer to the cell surface, we incubated HUVEC with anti-Tja serum (which contains antibodies against the Pk HUVECl None 0.03 x 105 0.6 x 10-9 TNF-a (500 U/mL) 9.4 x 105 1.7 x 10-9 HUVEC2 None 0.8 x 105 1.2 x 10-9 TNF-a(500U/mL) 11.3 x lo5 1.9 x 10-9
Binding of lZ5l-VT-l was performed at various concentrations (0.15 to 50.0 nmol/L) and with excess of unlabeled VT-1, in two independent HUVEC cultures. The number of binding sites for the holotoxin VT-1 and the apparent kd were calculated by analysis of Scatchard plots. [GbOse3cer], P [GbOse3cer], and PI blood group antigens). The addition of anti-Tja serum inhibited the binding of VT-1 in a concentration-dependent manner (Fig 8) . This finding was confirmed in three other experiments of HUVEC, as well as in femoral vein endothelial cells. Seven different human serum preparations from healthy donors did not decrease the binding of VT-1 to the endothelial cells. To ascertain whether the increase in VT-1 binding resulted from an increase in cellular GbOse3cer synthesis or from a change in the availability of GbOse3cer at the cell surface, HUVEC were incubated with and without TNF-a, and glycolipid extracts of cells were subsequently prepared. After TLC of these glycolipids, an increase in VT-1 binding at the spot of GbOse3cer was clearly demonstrated in the TNF-a-treated cells (Fig 9) . Occasionally, a second VT-1 binding band was observed, as demonstrated in Fig 9. Because the GbOse3cer in our standard sample sometimes appeared as two bands after mixture with the cellular extract, it is likely that the second band here is also (derived from) GbOse3cer. But the involvement of aOH-GbOse3cer, which has a similar Rf value as the second band and can also bind VT-1: cannot be excluded. GbOse3cer molecules in/on the cells has been markedly increased after preincubation with TNFa.
Requirement of Protein Synthesis for TNF-a-Induced VT-I Binding
The protein synthesis inhibitor cycloheximide was used to evaluate whether protein synthesis was required for the appearance of VT-1 receptors on the cell surface induced by TNF-a. The simultaneous addition of high concentrations of TNF-a and cycloheximide was toxic for the cells. However, it has been reported that partial protection for TNF-a cytotoxicity can be mediated by plasminogen activator inhibitor-2," the mRNA of which is rapidly induced in endothelial cells by TNF-a itself (own unpublished data). Therefore, we have added various concentrations of cycloheximide 3 hours after the addition of 20 U/mL TNF-a, and incubated the cells for another 21 hours. Subsequently, (Fig 10) . Similarly, in HUVEC, 0.5 and 2.0 pg/mL cycloheximide reduced the TNF-a-induced increase in VT-1 binding sites per cell by 58% and 73%, respectively (not shown). These data suggest that the TNF-a-induced increase in VT-1 receptors involves the induction of de novo synthesis of protein(s), that is (are) To evaluate how long confluent HUVEC have to be exposed to TNF-a to express an increase in VT-1 binding after 1 or 2 days, the cells were incubated for various times with 20 U/mL TNF-a, washed vigorously three times, and subsequently incubated without TNF-a for a residual time period until 24 hours (experiment 1) or 48 hours (experiment 2) after addition of TNF-a. Binding of 1 nmol/L '251-VT-l was determined with two different endothelial cell cultures, which had a threefold difference in basal VT-1 binding. Binding assay was performed as described in Materials and Methods.
For a molecule that has been recognized as a functional receptor for VT-1.5. 6 Two recent reports*lJ2 have demonstrated that human endothelial cells also become more sensitive to other related toxins, Shiga-like toxin I1 and Shiga toxin, when they are simultaneously exposed to TNF-a. Tesh et all1 have suggested that this may be due to a higher TNF-a susceptibility of endothelial cells whose protein synthesis was inhibited by VT-1. However, in our study, VT-1 was ineffective in untreated confluent endothelial cells, and only reduced protein synthesis in these cells when they were preincubated or coincubated with TNF-a. As the incubation with TNF-a resulted in a 10-to 100-fold increase in VT-1 receptors, it is likely that the reduction of protein synthesis and the increased cytotoxity caused by VT-1 is primarily the consequence of enhanced VT-1 binding to endothelial cells. Once the VT-1 binding sites are increased on the cell surface, the toxicity of TNF-a itself may act synergistically to the effect of VT-1.
Obrig et aI3O have observed that Shiga toxin has a higher cytotoxicity for subconfluent cells than for confluent cells. Our observation that subconfluent cells bind more VT-1 may correspond with this finding. However, it should be noted that the subconfluent cells were studied 24 hours after exposure to a strong proteolytic agent (trypsin, during passage of the cells), by which the cells certainly have been activated. Furthermore, as the half-life of endothelial cells in the normal adult human body is in the order of magnitude of 100 to 1,000 days,31 the pathophysiologic relevance of VT-1 cytotoxicity toward subconfluent cells will be limited to areas of neovascularization. Although our confluent cells displayed a low basal VT-1 binding, the amount of VT-1 binding was apparently not sufficient to interfere with the viability and protein synthesis of the endothelial cells.
Several hours' exposure of endothelial cells to TNF-a was enough to induce a detectable increase in VT-1 binding to these cells for 2 days. Therefore, an increase in endothelial VT-1 receptors may persist, even though inflammatory mediators are no longer detectable. No increase in concentrations of TNF-a and IL-1 could be established in the plasma of HUS patients on arrival at the hospitaP2 (own unpublished results). However, Siegler et a132 recently reported that TNF-a was elevated in the urine of HUS patients. This suggests that TNF-a may indeed have an effect in the kidneys of HUS patients. Possible local sources of TNF-a in the kidney are glomerular macrophage^^^ and mesangial cells.14J5 It is of interest to note that a study in mice on the toxicity of a related toxin, verocytotoxin-2 (Shiga-like toxin II), has suggested a role of TNF-a in the toxicity of this toxin.34 Mice defective in macrophage response to LPS, including a defective production of TNF-a, showed a consistently longer mean time to death than mice who were normally responsive. In addition, Barrett et al found that verocytotoxin-2 induced normal peritoneal macrophages to produce TNF-cx.~~ This may indicate that verocytotoxins act at various levels, ie, in activating macrophages to produce TNF-a and in damaging endothelial cells after the induction of their toxin receptors by TNF-a. It would be of great interest to know whether mesangial cells can also be induced to release TNF-a on exposure to verocytotoxins.
In addition to TNF-a, other inflammatory mediators, in particular IL-1, TNF-P, and LPS, also enhance VT-1 binding sites on endothelial cells. The parallel effects of these mediators on the synthesis of many endothelial proteins is well known.13 Coincubation of LPS with Shiga toxin resulted in one recent in more sensitive endothelial cells than with Shiga toxin alone, whereas in another study'* no additional effect was observed. Louise and Obrig12 reported that coincubation of IL-1 in combination with Shiga toxin did not result in an enhanced cell death. In contrast, unpublished experiments in our laboratory demonstrate that after 24 hours' preincubation of HUVEC with IL-la or IL-lP (5 or 50 U/mL), the endothelial viability becomes more sensitive toward VT-1, albeit less dramatical than toward 500 U/mL TNF-a. The variation in these data suggests that IL-1 and LPS, similar to TNF-a, can induce VT-1 receptors on endothelial cells, necessary to make these cells vulnerable to verocytotoxin, and that they act in concert with VT-1 on endothelial cell viability, but less profoundly than high concentrations of TNF-a. The combination of low concentrations of both LPS and TNF-a, which, in our study, caused a larger increase in the binding of VT-1 on the endothelial cells than did incubation with these mediators separately, may be of interest in HUS, because the patient may become exposed to very low concentrations of LPS during the prodromal phase of acute gastroenteritis. Fibrin has been seen in the histopathology of the kidney in HUS, and the presence of thrombin-antithrombin complexes (TAT), elevated levels of prothrombin fragment F1+2 (a marker of thrombin f~r m a t i o n ) ,~~ and increased concentrations of fibrinopeptide A3' are detectable in the plasma of HUS patients on admission. Therefore, we wondered whether thrombin may make HUVEC more sensitive to VT-1. This was not the case. The small increase in VT-1 binding caused by thrombin may be explained by the fact that thrombin can induce HUVEC to produce IL-la, which in turn will induce more VT-1 binding sites on the cell ~urface.~8
The endothelial binding of VT-1, induced by TNF-a, was inhibited by the presence of anti-Tja serum, which indicates that at least a major part of the specific VT-1 binding is a glycosphingolipid (GbOsescer). From VT-1 binding to cellular glycolipid extracts, which were separated by TLC, a large increase in the GbOse3cer content of TNF-a-treated endothelial cells was established. The increase must be due to an increase in GbOse3cer synthesis, rather than to a change in the availability of existing GbOse3cer on the cell surface, because the amount of GbOse3cer increased in the cellular extracts and the increase in binding could be prevented by simultaneous condition of cycloheximide. Therefore, we conclude that TNF-a induces one (or more) enzyme(s) that is (are) rate-limiting in the synthesis of GbOse3cer.
It is believed that the presence of verocytotoxins is necessary but not sufficient for the HUS development.' Our study suggests that one of the additional stimuli needed to develop the syndrome is the exposure of kidney endothelial cells to one or more of the inflammatory mediators TNF-a, IL-1, or LPS. We cannot yet discriminate whether the local availability of inflammatory mediators causes the preferential kidney damage of HUS in children, or whether the sensitivity of the endothelium in human glomeruli is larger than that of other endothelia. Endothelial cells of glomeruli For personal use only. on April 13, 2017. by guest www.bloodjournal.org From have only recently been isolated from animal kidneys,39 and isolation of these cells from human glomeruli is still in its infancy. However, in severe cases of HUS, not only kidney endothelial cells are affected, but also the endothelium in many other organs, including brain and pancreasa We therefore believe that our observations on the induction of verocytotoxin receptors on HUVEC are important for understanding the etiology of HUS, as well as for a better understanding of the biological actions of inflammatory mediators.
